A neurological examination can support a dementia evaluation, but it cannot diagnose dementia by itself and has no validated stand-alone accuracy percentage. U.S.
cost is not fixed; after concerning findings, the next step is a structured assessment with history, cognitive testing, laboratory work, and appropriate brain imaging. A dementia-focused neurological examination is a clinician's assessment of cognition, behavior, language, perception, movement, and sensation. It helps identify patterns and unusual signs that may change which tests or specialists are needed.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the examination can show
- Accuracy has no single percentage
- What the examination cannot determine
- Cost and Medicare coverage
- Practical next steps
What the examination can show
The examination helps characterize the person's cognitive-behavioral syndrome—the pattern of changes affecting thinking, behavior, or both. It may reveal language difficulty, altered perception, unusual behavior, or sensorimotor signs involving movement and sensation.
Atypical findings can make specialist referral more important. The Alzheimer's Association clinical practice guideline recommends interpreting the examination alongside a validated cognitive instrument, medical history, risk profile, and other findings.
Accuracy has no single percentage
A neurological examination does not produce a simple positive or negative result. Its value lies in the pattern of findings, so there is no validated sensitivity or specificity percentage for the examination alone. Cognitive screening tests have measurable performance, but their results are not equivalent to a diagnosis.
A meta-analysis of 149 studies reported 81% sensitivity and 89% specificity for MMSE dementia screening, according to JAMA Internal Medicine. Sensitivity describes how often a test detects dementia when it is present; specificity describes how often it is negative when dementia is absent. Those figures apply to the MMSE, not to the neurological examination or the complete diagnostic process. A normal brief cognitive score also does not exclude dementia when symptoms, functional changes, or history remain concerning.
What the examination cannot determine
The examination cannot establish the cause of cognitive changes on its own. Stroke, tumor, infection, medication effects, depression, and sleep problems can compete with or contribute to a suspected dementia syndrome; some may be treatable or reversible. First-line evaluation generally includes a tailored blood panel and structural brain imaging.
The Alzheimer's Association guideline prefers MRI without contrast when feasible, with CT used when MRI is unavailable or contraindicated. These additional tests do not replace the examination. They help clinicians look for explanations, contributors, or brain changes that cannot be established through bedside testing alone.
Cost and Medicare coverage
There is no single U.S. price for a dementia-focused neurological evaluation. Medicare payment for cognitive assessment and care planning under CPT 99483 varies by locality, according to CMS guidance revised January 15, 2026.
The service typically takes 50 minutes and includes a cognition-focused history and examination, functional and safety assessment, caregiver input, and a written care plan. It may be billed for beneficiaries with dementia, mild cognitive impairment, or clinician-judged cognitive impairment—even without a firm diagnosis. Laboratory tests, imaging, or specialist visits can expand the evaluation beyond that service. Before the appointment, ask which components are planned, whether they will be billed separately, and what coverage information the clinic needs.
Practical next steps
The uncertainty surrounding routine screening should not discourage evaluation of recognized symptoms. The USPSTF's finding of insufficient evidence applies to routine cognitive screening in asymptomatic, community-dwelling adults aged 65 or older—not to people already showing concerning changes. Prepare for the visit by gathering information that makes subtle changes easier to evaluate: If the initial findings are abnormal or remain concerning, request a structured follow-up cognitive assessment and care-planning visit rather than waiting for a firm diagnosis.
- Record specific examples of memory, language, judgment, behavior, or navigation problems.
- Note when each change began and whether it is worsening.
- Describe effects on medication use, finances, cooking, driving, or other daily tasks.
- Bring a complete medication list and relevant medical history.
- Ask whether a validated cognitive test, tailored blood work, and MRI or CT are appropriate.
